Optic Atrophy 1–Mediated Mitochondrial Hyperfusion Orchestrates Yes-Associated Protein 1 Nuclear Translocation to Sustain Ameloblastoma Stemness
The American Journal of Pathology · 2026
DOI: 10.1016/j.ajpath.2025.12.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Pathology, 2026. Verfasst von Jia-Jie Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key L…. Hauptthemen laut MEDLINE: GTP Phosphohydrolases, Neoplastic Stem Cells, Mitochondria, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 49 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Key Research and Development Program of Jiangxi Province.
Abstract (Originalsprache)
Ameloblastoma (AM), a locally aggressive odontogenic tumor, exhibits elusive pathogenesis. Here, optic atrophy 1 (OPA1)-mediated mitochondrial hyperfusion was identified as a driver of tumor stemness and progression. Single-cell transcriptomics of primary AM specimens revealed mitochondrial fusionHigh epithelial subpopulations exhibiting enriched stemness pathways. A striking up-regulation of OPA1 was observed in AM tissues, establishing a robust correlation between elevated OPA1 expression and up-regulated stemness markers, whereas functional experiments demonstrated that OPA1 overexpression amplifies self-renewal capacity and invasive aggression in human telomerase reverse transcriptase (hTERT)+-AM cells. Mechanistically, mitochondrial hyperfusion suppresses Hippo signaling, enabling yes-associated protein 1 (YAP1) nuclear translocation and TEA domain transcription factor (TEAD)-dependent transcription. OPA1-overexpressing cells exhibited robust nuclear YAP1 enrichment, driving stem-like expansion. Critically, clinical analysis established OPA1High tumors as having elevated growth rates, consolidating mitochondrial hyperfusion as a prognostic determinant. Therapeutically, MYLS22-a first-in-class OPA1 inhibitor-suppressed mitochondrial hyperfusion and reduced stemness in patient-derived organoids. The present work unveils an OPA1-mediated mitochondrial fusion-YAP1 nuclear translocation axis as the cornerstone of AM stemness, proposing OPA1 as a druggable target for this recalcitrant tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of Stomatology, Wuhan Un…
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Key Research and Development Program of Jiangxi Province
Zitieren
APA
Liang, J. J., Li, R. F., Bian, Y. H., Liu, L. X., Li, Z. J., Liu, B., & Zhang, L. Z. (2026). Optic Atrophy 1–Mediated Mitochondrial Hyperfusion Orchestrates Yes-Associated Protein 1 Nuclear Translocation to Sustain Ameloblastoma Stemness. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2025.12.002
Vancouver
Liang JJ, Li RF, Bian YH, Liu LX, Li ZJ, Liu B, et al. Optic Atrophy 1–Mediated Mitochondrial Hyperfusion Orchestrates Yes-Associated Protein 1 Nuclear Translocation to Sustain Ameloblastoma Stemness. The American Journal of Pathology. 2026. doi:10.1016/j.ajpath.2025.12.002
BibTeX
@article{Liang2026,
author = {Liang, Jia-Jie and Li, Rui-Fang and Bian, Yi-Han and Liu, Lu-Xuan and Li, Zhuo-Jian and Liu, Bing and Zhang, Lin-Zhou},
title = {Optic Atrophy 1–Mediated Mitochondrial Hyperfusion Orchestrates Yes-Associated Protein 1 Nuclear Translocation to Sustain Ameloblastoma Stemness},
journal = {The American Journal of Pathology},
year = {2026},
doi = {10.1016/j.ajpath.2025.12.002}
}
EUVIMED